Inpharma

Amodiaquine, alone or in combination, for malaria in pregnancy
pp. 1-1(1)

Meagre access to data regarding dietary supplements
pp. 2-2(1)

Industry-supported reviews: interpret with caution
pp. 3-3(1)

Antiretroviral price reductions possible
pp. 3-3(1)

Interaction between industry and physicians necessary
pp. 3-3(1)

Drugs major player in varying hospitalisation costs of CF
pp. 4-4(1)

Lopinavir/ritonavir superior choice for ART-experienced patients
pp. 4-4(1)

Natalizumab shows clinical, cost and QOL benefits
pp. 4-4(1)

Adding omalizumab to guideline recommended care may be cost effective in patients with severe allergic asthma
pp. 5-5(1)

Bupropion SR appears to be the most cost-effective smoking cessation therapy compared with nortriptyline and placebo
pp. 5-5(1)

IVF costs lowest with one embryo transfer
pp. 5-5(1)

Antihyperglycaemic use up but varied in Europe
pp. 5-5(1)

The glucagon-like peptide-1 analogue liraglutide effectively improves cardiovascular (CV) parameters in patients with type 2 diabetes mellitus
pp. 6-6(1)

Aliskiren ± ramipril lowers BP in patients with diabetes
pp. 6-6(1)

An erythropoietin receptor agonist [Hematide] has potential for the treatment of anaemia
pp. 6-6(1)

CERE 120 reduces symptoms of Parkinson's disease and is well tolerated
pp. 6-6(1)

The addition of DMXAA [AS 1404] to chemotherapy with carboplatin and paclitaxel is beneficial for patients with ovarian cancer
pp. 6-6(1)

Novel integrase inhibitor promising in triple-class resistant HIV-1
pp. 7-8(2)

Intra-articular magnesium appears to be an effective analgesic after arthroscopic surgery
pp. 9-9(1)

Granulocyte-macrophage colony-stimulating factor (GM-CSF) may improve the seroprotection of hepatitis B vaccine in end-stage renal disease
pp. 9-9(1)

A single dose of sildenafil has demonstrated efficacy in the treatment of Raynaud's disease associated with systemic scleroderma
pp. 9-9(1)

Histamine H2 receptor antagonists: from heartburn to heart failure?
pp. 9-9(1)

Monoclonal antibody G250 in combination with interferon-α-2a is beneficial for patients with renal cancer
pp. 9-9(1)

Magnesium sulfate for spasms, cardiac instability in tetanus
pp. 10-10(1)

Trazodone comparable to sertraline for major depression
pp. 10-10(1)

Peginterferon alfa for hepatitis delta
pp. 10-10(1)

TAnDEM treatment with trastuzumab plus anastrozole on top
pp. 11-12(2)

Systemic inosine pranobex [inosiplex] holds potential as a therapy for refractory cervical condylomata acuminata
pp. 12-12(1)

Extended-release (OROS) methylphenidate is more effective than SLI 381 [Adderall XR] for improving driving performance in adolescents with ADHD
pp. 12-12(1)

Adherence to metformin predicts diabetes outcome
pp. 12-12(1)

A buccal fentanyl tablet has demonstrated considerable efficacy for breakthrough pain in opioid-tolerant patients with chronic low back pain
pp. 12-12(1)

Metformin and thiazolidinediones are associated with a lower severity of coronary artery disease (CAD) than other standard treatments for diabetes
pp. 13-13(1)

Priming kids with last year's flu vaccine still boosts protection
pp. 13-13(1)

Fixed combination asthma inhalers improve therapy persistence
pp. 13-13(1)

Antipsychotics: efficacy vs tolerability for AD symptoms
pp. 13-13(1)

First-in-class glycylcycline broadens its horizons to CAP
pp. 15-16(2)

Infliximab appears to be more effective than etanercept for the treatment of refractory uveitis in children and adolescents
pp. 16-16(1)

Olanzapine vs quetiapine for schizophrenia
pp. 16-16(1)

Structured treatment interruption strategy effective for HIV infection
pp. 17-17(1)

Cinacalcet reduces hypercalcaemia in men with hyperparathyroidism secondary to kidney transplantation
pp. 17-17(1)

Esomeprazole beats other PPIs for reflux oesophagitis healing
pp. 17-17(1)

Bupropion vs venlafaxine: same for the head, different in bed
pp. 17-17(1)

Mercaptopurine "should remain the standard thiopurine in continuing therapy of childhood lymphoblastic leukaemia"
pp. 18-18(1)

Ciprofloxacin/dexamethasone ear drops are superior to oral amoxicillin/clavulanic acid for children with acute otitis media and otorrhoea
pp. 18-18(1)

Travoprost gets the `eye' vote for ocular hypertension
pp. 18-18(1)

Epoetin delta effective for anaemia in chronic kidney disease
pp. 18-18(1)

Green tea improves endothelial function and the number of circulating endothelial progenitor cells in healthy chronic smokers
pp. 19-19(1)

Buccal administration of misoprostol produces a reliable uterine response comparable to vaginal administration
pp. 19-19(1)

Combining simvastatin and pioglitazone improves a greater range of cardiovascular risk parameters in at-risk nondiabetic patients than each drug alone
pp. 19-19(1)

Rosiglitazone tops glibenclamide for microalbuminuria, BP reduction
pp. 19-19(1)

Ghrelin stimulates hunger and gastric emptying, but this effect does not appear to be mediated through growth hormone (GH)
pp. 19-19(1)

Pumping problem possible in pergolide-treated PD patients
pp. 20-20(1)

Tamsulosin, but not alfuzosin, reduces ejaculatory volume in healthy male subjects
pp. 20-20(1)

The incidence of postoperative ureteral obstruction appears to be rare after subureteral dextranomer/hyaluronan injection
pp. 20-20(1)

Fluvastatin: no increase in cancer risk
pp. 20-20(1)

Thiazolidinediones linked to bone loss in diabetic women
pp. 21-21(1)

`Sweeping' changes for the FDA proposed
pp. 21-21(1)

Childhood cancer survivors have long-term morbidity
pp. 22-22(1)

Growth hormone (GH) use appears to increase the risk of second neoplasms among childhood cancer survivors, but the risk appears to decrease with increasing length of follow-up
pp. 22-22(1)

US product approvals
pp. 22-22(1)

Other US regulatory news
pp. 23-23(1)

The European Medicines Agency has proposed that orphan drug status be granted to MediGene AG's paclitaxel [EndoTag 1] in pancreatic cancer.
pp. 23-23(1)

Triax Pharmaceuticals has launched Minocin Pac for acne in the US, a combination of minocycline [Minocin] tablets plus skin care products.
pp. 23-23(1)

Boston Scientific Corporation's everolimus-eluting coronary stent system [Promus] can be marketed in the 25 countries of the EU
pp. 23-23(1)